Lantern Pharma Announces Successful Early Completion of LP-300 Phase 2 HARMONIC™ Clinical Trial Enrollment in Japan

Reuters
31 Jul
Lantern Pharma Announces Successful Early Completion of LP-300 Phase 2 HARMONIC™ Clinical Trial Enrollment in Japan

Lantern Pharma Inc. has announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan, focusing on the treatment of non-small cell lung cancer (NSCLC) in never-smoker patients. The trial is evaluating the efficacy of LP-300 in combination with carboplatin and pemetrexed for patients whose cancer has progressed following treatment with tyrosine kinase inhibitors (TKIs). A total of 10 patients were enrolled ahead of schedule at five clinical sites, including the National Cancer Center Japan. Lantern Pharma is planning to release further clinical and outcome data from this trial later this quarter, which will cover both Asian and U.S. patient cohorts. The trial aims to address the unmet medical needs of this specific patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731092114) on July 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10